Mycophenolate Sodium for Primary Sjögren Syndrome
Author Information
Author(s): Willeke Peter, Schlüter Bernhard, Becker Heidemarie, Schotte Heiko, Domschke Wolfram, Gaubitz Markus
Primary Institution: Muenster University Hospital
Hypothesis
The study aims to evaluate the efficacy and safety of mycophenolate sodium (MPS) in patients with primary Sjögren syndrome (pSS) who are refractory to other treatments.
Conclusion
Mycophenolate sodium treatment may improve symptoms and some laboratory findings in patients with primary Sjögren syndrome, especially those with shorter disease duration.
Supporting Evidence
- Eight out of eleven patients tolerated the treatment well.
- Two patients dropped out due to side effects.
- Significant improvement in subjective measures of ocular dryness was observed.
- Laboratory tests showed a reduction in hypergammaglobulinemia and rheumatoid factors.
Takeaway
This study tested a medicine called mycophenolate sodium to see if it helps people with a condition that makes their eyes and mouth dry. It seems to help some people feel better.
Methodology
This was a single-center, open-label pilot trial with 11 patients treated with mycophenolate sodium for 6 months, with assessments at baseline, 3 months, and 6 months.
Potential Biases
Potential bias due to the open-label design and lack of a control group.
Limitations
The study had a small sample size and was not controlled.
Participant Demographics
All participants were women with a mean age of 50.1 years and a mean disease duration of 9.5 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website